Resumen

LISBOA, Ana  y  BRITO, Iva. Systemic Lupus erythematosus and pregnancy: therapeutic implications. Arq Med [online]. 2014, vol.28, n.1, pp.18-24. ISSN 2183-2447.

Systemic lupus erythematosus (SLE) is a multissystemic autoimmune disease predominantly affecting women in reproductive age. In order to reach a successful pregnancy, conception ideally should occur when the disease is in remission, with an adequate planning and close monitoring by a multidisciplinary team. One of the critical issues in managing pregnant women with SLE is choosing the right medication to treat the mother without harming the gestation. The most used drugs in SLE during pregnancy are corticosteroids, non-steroidal anti-inflammatory drugs and hydroxychloroquine. Immunomodulator medications like azathioprine, cyclosporine and tacrolimus can also be used, as well as intravenous immunoglobulin. Potentially teratogenic drugs are contraindicated, including cyclophosphamide, methotrexate and mycophenolate mofetil. The purpose of the present article is to review the main recommendations in SLE therapy during pregnancy and breastfeeding.

Palabras clave : Lupus erythematosus systemic; pregnancy; therapeutics.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )